/BLRX

BLRX Stock - BioLineRx Ltd.

Q: What is the analyst price target for BLRX?

Analyst price target information is not currently available for BLRX.

Q: What is BLRX's market cap?

Market capitalization information is not currently available for BLRX.

Healthcare|Biotechnology|NASDAQ

$3.04+2.70%

+$0.08 (+2.70%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.34

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BLRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.59

52W High$14.80

52W Low$2.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$28.94M	$4.80M	N/A	N/A	N/A
Gross Profit	$19.68M	$1.11M	N/A	N/A	N/A
Gross Margin	68.0%	23.1%	N/A	N/A	N/A
Operating Income	$-20,408,000	$-49,694,000	$-29,157,000	$-24,777,000	$-22,927,000
Net Income	$-9,221,000	$-60,614,000	$-24,951,000	$-27,054,000	$-30,021,000
Net Margin	-31.9%	-1262.8%	N/A	N/A	N/A
EPS	$-0.12	$-0.94	$-0.48	$-0.61	$-1.80

Company Overview

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Visit Website

Earnings History & Surprises

BLRX

Beat Rate

53%

Last 19 quarters

Avg Surprise

-260.5%

EPS vs Estimate

Beats / Misses

10/9

Last 12 quarters

Latest EPS

$-0.22

Q4 2025

EPS Surprise History

Q2 24

+96.6%

$-0.01vs$-0.29

Q3 24

+385.7%

$0.40vs$-0.14

Q4 24

-5500.0%

$-2.80vs$-0.05

Q1 25

+242.9%

$6.00vs$-4.20

Q2 25

+265.5%

$1.39vs$-0.84

Q3 25

-185.7%

$-1.00vs$-0.35

Q4 25

-173.0%

$-1.47vs$-0.54

Q4 25

+46.3%

$-0.22vs$-0.41

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.50	—	—	—
Q4 2025	Nov 24, 2025	$-0.41	$-0.22	+46.3%	✓ BEAT
Q4 2025	Nov 13, 2025	$-0.54	$-1.47	-173.0%	✗ MISS
Q3 2025	Aug 14, 2025	$-0.35	$-1.00	-185.7%	✗ MISS
Q2 2025	May 27, 2025	$-0.84	$1.39	+265.5%	✓ BEAT
Q1 2025	Mar 25, 2025	$-4.20	$6.00	+242.9%	✓ BEAT
Q4 2024	Nov 25, 2024	$-0.05	$-2.80	-5500.0%	✗ MISS
Q3 2024	Aug 15, 2024	$-0.14	$0.40	+385.7%	✓ BEAT
Q2 2024	May 28, 2024	$-0.29	$-0.01	+96.6%	✓ BEAT
Q1 2024	Mar 26, 2024	$-0.22	$-0.15	+31.8%	✓ BEAT
Q4 2023	Nov 20, 2023	$-7.20	$-12.00	-66.7%	✗ MISS
Q3 2023	Aug 30, 2023	$-6.40	$-12.00	-87.5%	✗ MISS
Q2 2023	May 24, 2023	$-5.60	$-6.00	-7.1%	✗ MISS
Q1 2023	Mar 22, 2023	$-5.60	$-3.60	+35.7%	✓ BEAT
Q4 2022	Nov 15, 2022	$-6.40	$-6.00	+6.3%	✓ BEAT
Q3 2022	Aug 16, 2022	$-5.60	$-6.40	-14.3%	✗ MISS
Q2 2022	May 11, 2022	$-6.00	$-4.00	+33.3%	✓ BEAT
Q1 2022	Mar 16, 2022	$-5.60	$-3.20	+42.9%	✓ BEAT
Q4 2021	Nov 18, 2021	$-5.20	$-9.20	-76.9%	✗ MISS
Q3 2021	Aug 18, 2021	$-4.80	$-6.00	-25.0%	✗ MISS